Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2025 Mar 2

PMID 40025324

Authors

Lauren M Perry

Varadan Sevilimedu

Natalia Polidorio

Nour Abuhadra

Monica Morrow

George Plitas

Stephanie Downs-Canner

Affiliations

Soon will be listed here.

Abstract

Background: The combination of pembrolizumab with neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) improves pathologic complete response (pCR) rates and event-free survival. Yet it is unclear which patients benefit most from the addition of immunotherapy. This study aims to identify predictive factors for pCR in patients with TNBC receiving chemo-immunotherapy (chemo-IO).

Patients And Methods: This single-institution retrospective analysis included 283 consecutive patients with TNBC treated with neoadjuvant chemo-IO from 1 June 2021 to 20 January 2023. The primary outcome was overall pCR; secondary outcomes were breast pCR and nodal pCR. Univariate and multivariable logistic regression models assessed for characteristics associated with overall, breast, or nodal pCR.

Results: Most patients presented with cT2 (71%) cN0 (54%) disease. The overall pCR rate was 57%, breast pCR was 58%, and axillary pCR was 67% among biopsy-proven cN+ patients. Race, pathogenic BRCA mutations, backbone chemotherapy regimen, immune-related adverse events, and disruptions in immunotherapy were not associated with pCR. Univariate associations with overall pCR were younger age (p = 0.04), lower clinical T stage (p = 0.01), ductal histology (p < 0.001), poor differentiation (p < 0.001), and unifocality (p < 0.001). Breast and axillary pCR had similar associations. Nodal pCR also had univariate associations with normal body mass index (BMI) (p = 0.04) and absence of lymphovascular invasion (LVI) (p = 0.04). On multivariable analyses, ductal histology and unifocality remained independently associated with overall and breast pCR.

Conclusions: This analysis showed few clinical variables to be independently associated with pCR after neoadjuvant chemo-IO for TNBC. Thus, predicting chemo-IO response to personalize treatment and minimize morbidity may instead lie in ongoing basic and translational research to assess for useful biomarkers.

References

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Hudis C, Gianni L . Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1:1-11. DOI: 10.1634/theoncologist.2011-S1-01. View

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C . Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022; 387(3):217-226. DOI: 10.1056/NEJMoa2202809. View

Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M . Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022; 33(5):534-543. DOI: 10.1016/j.annonc.2022.02.004. View

Mittendorf E, Zhang H, Barrios C, Saji S, Jung K, Hegg R . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase.... Lancet. 2020; 396(10257):1090-1100. DOI: 10.1016/S0140-6736(20)31953-X. View

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022; 386(6):556-567. DOI: 10.1056/NEJMoa2112651. View

10.

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S . Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024; 391(21):1981-1991. DOI: 10.1056/NEJMoa2409932. View

11.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View

12.

Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A . Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017; 3(10):1378-1385. PMC: 5710508. DOI: 10.1001/jamaoncol.2017.1007. View

13.

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

14.

Boutros C, Tarhini A, Routier E, Lambotte O, Leroy Ladurie F, Carbonnel F . Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473-86. DOI: 10.1038/nrclinonc.2016.58. View

15.

Benchimol E, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I . The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015; 12(10):e1001885. PMC: 4595218. DOI: 10.1371/journal.pmed.1001885. View

16.

Mai N, Myers S, Shen S, Downs-Canner S, Robson M, Norton L . Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. NPJ Breast Cancer. 2024; 10(1):39. PMC: 11150442. DOI: 10.1038/s41523-024-00643-5. View

17.

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16(8):2672-85. DOI: 10.1200/JCO.1998.16.8.2672. View

18.

Eisner Z, Best C, Lenders J, Hespe G, Myers P, Kung T . Cross-Sectional Analysis of Patients Referred to a Tertiary Lymphatic Surgery Center. Ann Surg Oncol. 2024; 32(1):542-550. DOI: 10.1245/s10434-024-16304-7. View

19.

Wood S, Gao Y, Lee J, Chen J, Wang Q, Meisel J . High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res Treat. 2024; 205(1):193-199. DOI: 10.1007/s10549-023-07233-2. View

20.

Woodfin A, Yam C, Teshome M, Kuerer H, Hunt K, Meric-Bernstam F . Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2023; 31(2):974-980. DOI: 10.1245/s10434-023-14541-w. View